BioSpace News Archive

Biotech Bay

Why Bay Area’s XOMA Surged 700% in 2017 by Not Making Drugs

The company burned through $1.2B and never brought a drug to market in its 37 years.

January 26, 2018
·
4 min read
·
Mark Terry
Deals

J&J Bows Out of Race for Pfizer’s $20B Consumer Health Biz

Now insiders say J&J has decided it is no longer interested.

January 26, 2018
·
2 min read
·
Mark Terry
BioCapital

Incoming Novartis CEO, Bayer Leader Join President Trump for Private Dinner at Davos

During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.

January 26, 2018
·
2 min read
·
Alex Keown
Business

Kalytera Announces Issuance of Shares Under Services Agreement With The Salzman Group of Israel

Under the deal, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.

January 26, 2018
·
3 min read
AmoyDx’s Plasmid Diagnostic for EGFR Mutations Approved in China

Last year, AmoyDx’s EGFR diagnostic was approved for use in the EU.

January 26, 2018
·
1 min read
Drug Development

Amgen Continues to be a Force to be Reckon With When It Comes to Migraines

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.

January 26, 2018
·
1 min read
Policy

Puma Hits a Huge Roadblock

Despite some safety concerns such as severe diarrhea, the FDA approved Puma’s breast cancer drug Nerlynx in July 2017.

January 26, 2018
·
1 min read
Primus Announces a Voluntary Nationwide Recall of All Lots Within Expiry of Prescription Medical Food Limbrel Due to Rare But Serious and Reversible Adverse Events

Primus is notifying its distributors by emailed letter and is arranging for the return of all recalled products.

January 26, 2018
·
4 min read
Deals

CASI Pharma Acquires ANDA Portfolio From Sandoz

CASI intends to select and commercialize certain products from the portfolio that have unique market opportunity and cost-effective manufacturing in China and/or in the U.S.

January 26, 2018
·
5 min read
Biotech Beach

Innovus Pharmaceuticals, Inc. Issues Statement Regarding Recent Market Activity Concerning Its Common Stock

Innovus Pharmaceuticals announces that it was made aware of and requested by the OTC Markets Group Inc. to comment on recent market activity concerning shares of INNV common stock.

January 26, 2018
·
5 min read